OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 2,848 results

Filters: bromodomain inhibitors

Identification of novel Bromodomain inhibitors of Trypanosoma cruzi Bromodomain Factor 2 (TcBDF2) using a fluorescence polarization-base high-throughput assay
Serra, E. C.; Tavernelli, L.; Alonso, V. L.; Pena, I.; Rodriguez Araya, E.; Manarin, R.; Cantizani, J.; Martin, J.; Salamanca, J.; Bamborough, P.; Calderon, F.; Gabarro, R.
biorxiv. 2024-02-18. Preprint
Source:biorxiv
PPRID: 10.1101/2024.02.16.580721v1 doi:NA
Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation.
Ting Ran, Zhimin Zhang, Kejun Liu, Yi Lu, Huifang Li, Jinxing Xu, Xiao Xiong, Yanmin Zhang, Anyang Xu, Shuai Lu, Haichun Liu, Tao Lu, Yadong Chen
Mol Biosyst. May, 2015.11(5):1295-304 Print
Source:PubMed
PMID: 25758752 doi:10.1039/c4mb00723a
Integrated virtual screening and MD simulation approaches toward discovering potential inhibitors for targeting BRPF1 bromodomain in hepatocellular carcinoma.
Soumen Barman, Ishita Bardhan, Jyotirmayee Padhan, Babu Sudhamalla
J Mol Graph Model. 01, 2024.126:108642 Print-Electronic
Source:PubMed
PMID: 37797430 doi:10.1016/j.jmgm.2023.108642
Bromodomain inhibitors: what does the future hold?
Seemana Bhattacharya, Sujan Piya, Gautam Borthakur
Clin Adv Hematol Oncol. Jul, 2018.16(7):504-515 Print
Source:PubMed
PMID: 30067623 doi:
Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family.
Mostafa Radwan, Rabah Serya
Arch Pharm (Weinheim). Aug, 2017.350(8): Print-Electronic
Source:PubMed
PMID: 28714212 doi:10.1002/ardp.201700147
The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
Kazuki Sasaki, Minoru Yoshida
Drug Discov Today Technol. Mar, 2016.19:51-56 Print-Electronic
Source:PubMed
PMID: 27769358 doi:10.1016/j.ddtec.2016.06.001
Overexpression of bromodomain factor 3 in Trypanosoma cruzi (TcBDF3) affects differentiation of the parasite and protects it against bromodomain inhibitors.
Victoria Lucia Alonso, Carla Ritagliati, Pamela Cribb, Julia Alejandra Cricco, Esteban Carlos Serra
FEBS J. 06, 2016.283(11):2051-66 Print-Electronic
Source:PubMed
PMID: 27007774 doi:10.1111/febs.13719
Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms.
Qianqian Wang, Xiaomin Shao, Elaine Lai Han Leung, Yingqing Chen, Xiaojun Yao
Pharmacol Res. 10, 2021.172:105804 Print-Electronic
Source:PubMed
PMID: 34450309 doi:10.1016/j.phrs.2021.105804
BET Bromodomain Inhibitors Target the NEUROD1-subtype SCLC by Blocking NEUROD1 Transactivation
Chen, H.; Gesumaria, L.; Park, Y.-K.; Oliver, T. G.; Singer, D. S.; Ge, K.; Schrump, D. S.
biorxiv. 2021-10-25. Preprint
Source:biorxiv
PPRID: 10.1101/2021.10.25.465771v1 doi:NA
Bromodomain inhibitors a decade later: a promise unfulfilled?
Monica M Mita, Alain C Mita
Br J Cancer. 12, 2020.123(12):1713-1714 Print-Electronic
Source:PubMed
PMID: 32989227 doi:10.1038/s41416-020-01079-x
0